Profil
Helen Milton formerly worked at Keryx Biopharmaceuticals, Inc., as Vice President-Global Regulatory Affairs & Quality from 2014 to 2017, AMAG Pharmaceuticals, Inc., as Senior VP-Regulatory Affairs & Quality in 2020, Mallinckrodt Pharmaceuticals, as Senior VP-Regulatory Affairs & Pharmacovigilance from 2021 to 2022, and Viridian Therapeutics, Inc., as Senior Vice President-Regulatory Affairs from 2023 to 2024.
Dr. Milton received her undergraduate degree and doctorate degree from The University of Liverpool.
Anciens postes connus de Helen Milton
| Sociétés | Poste | Fin |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Conseiller Juridique Général | 02/01/2024 |
| AMAG PHARMACEUTICALS, INC. | Conseiller Juridique Général | 01/12/2020 |
| KERYX BIOPHARMACEUTICALS | Conseiller Juridique Général | 01/05/2017 |
Formation de Helen Milton
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
















